For the quarter ending 2025-12-31, NMTC had -$3,008,766 decrease in cash & cash equivalents over the period. -$3,156,589 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net (loss) income | -1,437,890 | -1,619,221 | -1,986,153 |
| Amortization and depreciation | 65,523 | 64,324 | 197,355 |
| Amortization of deferred issuance costs | - | 0 | 192,647 |
| Stock-based compensation | 359,255 | 358,560 | 906,048 |
| Fair value change in warrant liability | -222,740 | 314,751 | -1,099,421 |
| Debt and equity facility costs reclassified to financing activities | - | 141,416 | - |
| Non-cash lease expense | 28,944 | 28,426 | 83,187 |
| Valuation adjustments for excess or obsolete inventory | - | 2,500 | 7,500 |
| Accounts receivable | 1,397,062 | 1,264,805 | -176,636 |
| Inventory | -560,658 | 331,604 | -729,952 |
| Prepaid expenses | 13,155 | -91,991 | 16,902 |
| Accounts payable | -439,992 | 526,943 | -286,960 |
| Debt and equity facility termination costs reclassed to financing activities | - | - | 141,416 |
| Accrued expenses, operating leases and other liabilities | -619,376 | 302,463 | -356,905 |
| Net cash (used in) provided by operating activities | -3,115,835 | -1,525,672 | -1,311,600 |
| Purchase of property and equipment | 40,754 | 10,607 | 71,135 |
| Net cash used in investing activities | -40,754 | -10,607 | -71,135 |
| Proceeds from issuance of common stock attributed to non-private placement equity offerings | - | 9,614,037 | - |
| Issuance costs attributed to common stock and warrants issued in private placement | - | 185,903 | - |
| Issuance costs related equity financings | - | - | 1,231,873 |
| Issuance costs related to non-private placement equity offerings | - | 1,045,971 | - |
| Deferred issuance costs in connection with debt facility | - | 0 | 297,942 |
| Exercise of warrants | 174,375 | 69,750 | - |
| Proceeds from issuance of common stock attributed to equity financings | - | - | 9,614,037 |
| Deferred issuance costs in connection with at-the-market offering program | 22,920 | - | - |
| Share repurchases for the payment of employee taxes | 3,632 | 2,771 | 121,846 |
| Net cash provided by (used in) financing activities | 147,823 | 66,978 | 7,962,376 |
| Net decrease in cash | -3,008,766 | -1,469,301 | 6,579,641 |
| Cash and cash equivalents at beginning of period | 6,570,382 | 1,460,042 | - |
| Cash and cash equivalents at end of period | 3,561,616 | 6,570,382 | - |
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)